metformin has been researched along with 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Arora, S; Chaturvedi, A; Heuser, M; Joshi, G; Kumar, R; Patil, S | 1 |
| Bhamra, GS; Carr, RD; Davidson, SM; Hausenloy, DJ; Mocanu, MM; Paiva, M; Wynne, AM; Yellon, DM | 1 |
| Edgerton, SM; Fan, Z; Lind, SE; Liu, B; Thor, AD; Yang, X | 1 |
| Chan, DW; Li, C; Liu, VW; Ngan, HY; Yao, KM | 1 |
| Du, J; Li, X; Ren, F; Shi, HR; Wang, JL; Wu, QH; Zhang, RT | 1 |
| Borin, TF; Carvalho, LGS; de Campos Zuccari, DAP; Ferreira, LC; Gelaleti, GB; Hellmén, E; Jardim-Perassi, BV; Leonel, C; Maschio-Signorini, LB; Moschetta, MG; Sonehara, NM | 1 |
| Han, W; Li, Y; Wang, H; Wang, Q; Wu, Y; Xiao, J; Xie, L; Xu, H; Xu, K; Yuan, Y; Zhang, H; Zheng, Z; Zhou, K | 1 |
| Athari, SS; Ma, B; Mehrabi Nasab, E; Zhao, L | 1 |
8 other study(ies) available for metformin and 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
| Article | Year |
|---|---|
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
Topics: Allosteric Regulation; Allosteric Site; Carrier Proteins; Chemistry, Pharmaceutical; Glycolysis; Humans; Membrane Proteins; Protein Kinase Inhibitors; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2022 |
Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening.
Topics: Animals; Chromones; Diabetes Mellitus; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Hypoglycemic Agents; Ischemic Contracture; Male; Metformin; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Morpholines; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Oxidative Stress; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar | 2008 |
Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Dasatinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Immunoprecipitation; Metformin; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pyrimidines; Receptor, ErbB-2; Receptor, IGF Type 1; Signal Transduction; Thiazoles; TOR Serine-Threonine Kinases; Trastuzumab | 2011 |
LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Proliferation; Chromones; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Enzyme Inhibitors; Female; Flow Cytometry; Humans; Metformin; Morpholines; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Poly(ADP-ribose) Polymerases; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2012 |
Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chromones; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Inhibitory Concentration 50; Metformin; Mice; Mice, Nude; Morpholines; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Evaluation of Angiogenesis Process after Metformin and LY294002 Treatment in Mammary Tumor.
Topics: Animals; Cell Line, Tumor; Chromones; Cobalt; Dog Diseases; Dogs; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Mammary Neoplasms, Animal; Metformin; Mice; Mice, Inbred BALB C; Mice, Nude; Morpholines; Neovascularization, Pathologic; Oxygen; Vascular Endothelial Growth Factor A | 2019 |
Metformin Promotes Axon Regeneration after Spinal Cord Injury through Inhibiting Oxidative Stress and Stabilizing Microtubule.
Topics: Animals; Axons; Chromones; Metformin; Microtubules; Mitochondria; Morpholines; NF-E2-Related Factor 2; Oxidative Stress; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Regeneration; Response Elements; Spinal Cord Injuries | 2020 |
PI3K/AKT/mTOR and TLR4/MyD88/NF-κB Signaling Inhibitors Attenuate Pathological Mechanisms of Allergic Asthma.
Topics: Animals; Anti-Asthmatic Agents; Asthma; Chromones; Female; Metformin; Mice; Mice, Inbred BALB C; Morpholines; Myeloid Differentiation Factor 88; Naphthyridines; NF-kappa B; Ovalbumin; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Toll-Like Receptor 4; TOR Serine-Threonine Kinases | 2021 |